[NH:1]1[C:5]2[CH:6]=[CH:7][CH:8]=[CH:9][C:4]=2[N:3]=[C:2]1[C:10]([OH:12])=O.Cl.[NH:14]1[CH2:17][CH:16]([C:18]2[C:23]([Cl:24])=[N:22][CH:21]=[CH:20][N:19]=2)[CH2:15]1.CN(C(ON1N=NC2C=CC=NC1=2)=[N+](C)C)C.F[P-](F)(F)(F)(F)F.CCN(CC)CC.C([O-])([O-])=O.[Na+].[Na+]>C(Cl)Cl.O.CC#N>[NH:3]1[C:4]2[CH:9]=[CH:8][CH:7]=[CH:6][C:5]=2[N:1]=[C:2]1[C:10]([N:14]1[CH2:17][CH:16]([C:18]2[C:23]([Cl:24])=[N:22][CH:21]=[CH:20][N:19]=2)[CH2:15]1)=[O:12]A mixture of 1H-benzoimidazole-2-carboxylic acid (19) (100 mg, 0.47 mmol), 2-azetidin-3-yl-3-chloro-pyrazine hydrochloride (8) (96 mg, 0.47 mmol), HATU (540 mg, 1.3 mmol) and Et3N (101 mg, 1 mmol) in dry DCM (10 mL) was stirred at RT overnight. Then the mixture reaction was poured into saturated aqueous Na2CO3 and extracted with DCM (50 mL×3), the organic layer was washed with brine, dried over Na2SO4 and concentrated to give the crude compound which was purified by ISCO silica gel column (10% to 80% EtOAc in petroleum ether) and followed by reverse phase prep. HPLC (10% to 80% water/MeCN) to afford pure (1H-benzoimidazol-2-yl)-[3-(3-chloro-pyrazin-2-yl)-azetidin-1-yl]-methanone (84) (50 mg, 0.16 mmol, yield 34%).